Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29631941 | 0.83 | MAPT (0.46) | PTGS2MAPTL3MBTL1NR1H2 | |
| SCHEMBL29631943 | 0.83 | L3MBTL1 (0.60) | PTGS2L3MBTL1KDM4ENR1H2 | |
| SCHEMBL19013605 | 0.83 | L3MBTL1 (0.60) | PTGS2L3MBTL1KDM4ENR1H2 | |
| SCHEMBL30597746 | 0.83 | L3MBTL1 (0.44) | PTGS2MAPTL3MBTL1GABRG2GABRB3 | |
| SCHEMBL19013038 | 0.83 | MAPT (0.46) | PTGS2MAPTL3MBTL1NR1H2 | |
| SCHEMBL24671812 | 0.82 | KDM4E (0.38) | PTGS2GABRG2GABRB3GABRA5KDM4E | |
| SCHEMBL30066574 | 0.82 | KDM4E (0.38) | PTGS2GABRG2GABRB3GABRA5KDM4E | |
| SCHEMBL6617414 | 0.82 | L3MBTL1 (0.43) | PTGS2L3MBTL1AURKACDK2GABRG2 | |
| SCHEMBL29631894 | 0.82 | PTGS2 (0.51) | PTGS2MAPTL3MBTL1AURKACDK2 | |
| SCHEMBL19013033 | 0.82 | PTGS2 (0.51) | PTGS2MAPTL3MBTL1AURKACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332701-A1 | HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | ASCENTAGE PHARMA GROUP CORP LIMITED (HK) | 2022-10-20 | — | — | US | disclosed |
| CN-112300129-B | Heterocyclic compounds as BCR-ABL inhibitors | 苏州亚盛药业有限公司 | 2021-09-14 | — | — | CN | disclosed |
| WO-2021018194-A1 | HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-02-04 | — | — | WO | disclosed |
| CN-112300129-A | Heterocyclic compounds as BCR-ABL inhibitors | 苏州亚盛药业有限公司 | 2021-02-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332701-A1 | HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | ABL1, ABL2, BCR | PTGS2 4540/4885MAPT 3878/4885L3MBTL1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.